Resources and Information
»Glaucoma Watch STAGING
Case Presentation: Laser Imaging Detects Early ON Damage
Optic nerve damage can be detected long before visual field data uncovers the problem. Read the full case, courtesy of Heidelberg Engineering.
read more
»Clinical Guidelines STAGING
Re-Defining Ocular Hypertension
Is one standard deviation above a mean (IOP>21mm) too simplistic a definition of ocular hypertension?
read more
»Glaucoma Watch STAGING
Optic Nerve Head Measurements with the HRT III
African-American and Hispanic populations have been found to be at greater risk for developing glaucoma, yet the original database for derivation of HRT II stereometric parameters consisted of only Caucasians. The new HRT III database has been expanded to include African-Americans and individuals of Indian (Southeast Asian) origin. Further additions of Hispanic and Asian populations are underway.
read more
»Glaucoma Watch STAGING
NGS Residency Award and Lecture
The National Glaucoma Society is inviting current residents in optometry and ophthalmology to submit a presentation for a 30-minute lecture at the National Glaucoma Symposium to be held July 28-30, 2007 at the Ocean Edge Resort, Cape Cod, MA.
read more
»Industry News STAGING
Alcon's Travatan Z and Systane Use Different Preservatives
Alcon Laboratories' voluntary recall of SYSTANE free LIQUID GEL Lubricant Eye Drops does not affect other Alcon products such as TRAVATAN Z.
<br/>
read more
»Clinical Guidelines STAGING
Beta Blockers in Glaucoma Management
At a recent NGS seminar, the implications of systemic and topical beta blockers were discussed. Useful guidelines and clinical pearls were highlighted.
read more: Full Members Only
»Glaucoma Watch STAGING
Case Presentation: Optic Nerve Imaging
A 48-year-old patient with symmetrical optic nerve appearances and equal IOP’s demonstrated only monocular functional loss. Optic nerve imaging was able to localize the defect and permit earlier intervention.
read more
»Industry News STAGING
Alcon's Travatan Z Solution Receives FDA Approval
Alcon, Inc has just announced that the FDA has approved Travatan Z for treatment of glaucoma and ocular hypertensive patients.
read more